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EssentialsPersistence of DOACs in every day clinical practice may be lower than reported in trials.In this cohort study of atrial fibrillation patients 34% stopped their DOAC within 12 months.Young age, female sex and non‐adherence to DOAC were predictors of non‐persistence to DOAC.Clinicians should be aware of the low persistence to DOAC in patients with atrial fibrillation.

1. INTRODUCTION {#rth212261-sec-0007}
===============

In the Netherlands, approximately 300 000 people receive oral anticoagulant drugs (ie, 1.8% of the population) for the prevention of embolic stroke in atrial fibrillation[1](#rth212261-bib-0001){ref-type="ref"}. Currently, the majority of these patients is using vitamin K antagonist (VKA) treatment, but the proportion of direct oral anticoagulant (DOAC) users is steadily rising[2](#rth212261-bib-0002){ref-type="ref"}. DOACs are registered as drugs that can be taken in fixed doses which do not require routine testing to evaluate the anticoagulation effect. This is an important advantage over VKAs which need to be monitored and titrated on a regular basis. Although the efficacy of DOACs has been proven, the discontinuation or persistence rate will determine its successfulness, especially because the efficacy can be affected by even one delayed or missed dose[3](#rth212261-bib-0003){ref-type="ref"}, [4](#rth212261-bib-0004){ref-type="ref"}, [5](#rth212261-bib-0005){ref-type="ref"}, [6](#rth212261-bib-0006){ref-type="ref"}, [7](#rth212261-bib-0007){ref-type="ref"}. A recently published nationwide observational study from New Zealand showed that persistence was poor in DOAC users (n = 43 339 dabigatran users), with as many as 41% of atrial fibrillation patients who discontinued dabigatran over a 2 year follow‐up period[8](#rth212261-bib-0008){ref-type="ref"}. In addition, in a study from the United States, 32% of patients with atrial fibrillation discontinued with dabigatran at 6 months, increasing to nearly 50% by 1 year[9](#rth212261-bib-0009){ref-type="ref"}. This is in stark contrast to the discontinuation rate in the clinical trials where only 21%--25% of patients with atrial fibrillation were non‐persistent to DOAC treatment at 2 years of follow‐up[10](#rth212261-bib-0010){ref-type="ref"}, [11](#rth212261-bib-0011){ref-type="ref"}, [12](#rth212261-bib-0012){ref-type="ref"}. In a recent observational study, including 25 976 patients with atrial fibrillation, Jackevicius et al[13](#rth212261-bib-0013){ref-type="ref"} found an association between non‐persistence of DOAC and adverse cardiovascular outcomes, with a 4‐6 fold increased risk of stroke/transient ischaemic attack (TIA) when patients were non‐persistent to dabigatran or rivaroxaban. Another study suggested that the lower discontinuation rate of DOACs in clinical trials compared with the daily clinical situation can be explained by efforts in such trials to minimize non‐persistence by means of telephone or face to face contact[14](#rth212261-bib-0014){ref-type="ref"}. Such intensive patient care practice resembles the routine care for VKA users by anticoagulation clinics such as in the Netherlands, which has been proven to be efficient for other preventive cardiovascular drugs as well, like clopidogrel, beta blockers and statins[15](#rth212261-bib-0015){ref-type="ref"}. Obviously, for the same level of efficacy of DOACs in phase III trials to be translated into clinical practice, the same level of DOAC persistence is required.

We therefore aimed to explore the persistence to DOACs in community dwelling patients with atrial fibrillation from 1 April 2012 to 1 April 2016 in the Netherlands. We contrasted these findings to a cohort of patients with atrial fibrillation who were treated at the Leiden Anticoagulation Clinic, the Netherlands, between 2004 and 2011 (ie at a time when only VKA was available and patients could not switch to DOAC). Of note, VKA was only included as a reference cohort and not to directly compare between DOAC or VKA users as such comparisons would be confounded (by indication)[16](#rth212261-bib-0016){ref-type="ref"}.

2. METHODS {#rth212261-sec-0008}
==========

2.1. Population description {#rth212261-sec-0009}
---------------------------

Patterns of drug use can be studied from pharmacy dispensing data[17](#rth212261-bib-0017){ref-type="ref"}. In the Netherlands, the Foundation for Pharmaceutical Statistics (SFK) gathers pharmacy dispensing data from \>95% of community pharmacies to monitor medication prescriptions and does not contain information about clinical indication or outcome[18](#rth212261-bib-0018){ref-type="ref"}. SFK data provides detailed information on the drugs dispensed, including the codes from the Anatomic--Therapeutic--Chemical (ATC) system of the World Health Organization, the prescribed dose, and the amount dispensed. In the current study, data on DOAC use (by ATC code), with the DOAC dose, number of tablets dispensed, date of dispensing, patient\'s sex, age, any concomitant medical therapy, and if a patient used VKA prior to DOAC initiation or switched to VKA during follow‐up, were collected[19](#rth212261-bib-0019){ref-type="ref"}. Four digit postal codes of the patients were also provided by SFK, which allowed us to characterize neighbourhood socioeconomic status. The latter information was retrieved by using information from the Netherlands Institute of Social Research, which keeps record of neighbourhood socioeconomic status by use of 4‐digit postcodes[20](#rth212261-bib-0020){ref-type="ref"}.

As a comparison, we also included a cohort of patients with atrial fibrillation who received anticoagulant treatment with VKAs at the Anticoagulation Clinic in Leiden, the Netherlands. In this cohort, age at VKA initiation, sex and indication for which the VKA was prescribed (atrial fibrillation) were provided.

2.2. Inclusion criteria {#rth212261-sec-0010}
-----------------------

We included all patients who had at least one dispensing of the DOAC agents dabigatran and rivaroxaban from 1st of January 2012 until 1st of April 2016. The DOAC apixaban was registered in the Netherlands in April 2013 for the prevention of systemic embolism in atrial fibrillation. Therefore, all available patient information on apixaban use ranged between 1 April 2013 and 1 April 2016. The DOAC edoxaban was not included since it was not yet approved in the Netherlands during the time period studied. Only incident (first time) DOAC users were included in this study.

In the VKA only cohort, all patients who started with VKA treatment between 1 January 2004 and 31 December 2011 were included and were followed for 4 years or until they ceased VKA treatment or until 1 January 2012, whichever date came first. We specifically chose this time period because only VKAs were available for oral anticoagulation then. Therefore, these patients could not discontinue their drug due to a switch to a DOAC (as was possible from 2012 onwards). Hence, we could estimate the expected non‐persistence rate in a generalizable group of patients with atrial fibrillation who were prescribed oral anticoagulants at an anticoagulation clinic in the Netherlands.

2.3. Exclusion criteria {#rth212261-sec-0011}
-----------------------

To ensure that only incident DOAC users were included, we excluded patients who received a DOAC between 1 January 2012 and 1 April 2012. Although SFK does not list the clinical indications for the drugs dispensed, the indication could be assessed by the first dose of DOAC, which is different for short term thromboprophylaxis (ie patients who undergo orthopaedic surgery and receive DOAC treatment for a maximum of 10‐38 days), venous thrombosis treatment and thromboembolic prevention in atrial fibrillation patients (see Table [S1](#rth212261-sup-0001){ref-type="supplementary-material"})[20](#rth212261-bib-0020){ref-type="ref"}. In the current study, only patients who were identified as atrial fibrillation patients were included. Of note, patients who used apixaban 2.5 mg twice daily (bid) for less than 6 weeks could both use it for thromboprophylaxis or for thromboembolic prevention in atrial fibrillation. Since we could not distinguish between these two indications, these patients (n = 361 apixaban users) were excluded from further analysis.

2.4. Exposure variables {#rth212261-sec-0012}
-----------------------

Patients were classified as dabigatran, rivaroxaban or apixaban users if they received at least one dispensing of ATC codes B01AE07, B01AF01 or B01AF02, respectively. DOACs can be administered to patients with atrial fibrillation in different dosages[21](#rth212261-bib-0021){ref-type="ref"}. For this purpose we classified dabigatran users as high dose users when they received a first dabigatran prescription of 150 mg bid, and as low dose users when they took 110 mg bid as a first dabigatran prescription. For rivaroxaban, high dose was defined as rivaroxaban 20 mg once daily (od), and low dose as rivaroxaban 15 mg od. For apixaban, high dose was defined as 5 mg bid, and low dose as 2.5 mg bid. For the VKA only cohort, we received information from the Leiden anticoagulation clinic where patients either used phenprocoumon or acenocoumarol; of which the large majority used phenprocoumon.

2.5. Concomitant variables {#rth212261-sec-0013}
--------------------------

If patients on DOAC had received VKA (ATC code B01AA) or used concomitant medication within 180 days prior to baseline, we defined them as experienced VKA user or concomitant drug user, respectively. Neighbourhood socioeconomic status was gathered by using the database "status score" from the Netherlands Institute for Social Research[22](#rth212261-bib-0022){ref-type="ref"}. The "status score" of a neighbourhood (postal code area) is based on (a) mean household income, (b) the percentage of households with a low income, (c) the percentage of inhabitants without a paid job and (d) the percentage of households with on average a low education. The status score combines these four variables into a continuous variable where the higher the score, the higher the socioeconomic status of a neighbourhood is. We a‐priori defined a high neighbourhood socioeconomic status as \>90th percentile of status score in the SFK data.

Patient adherence to DOAC was measured as a dichotomous variable for the proportion of days covered (PDC) of at least 80%. This PDC cut‐off is consistent with published research[2](#rth212261-bib-0002){ref-type="ref"}, [4](#rth212261-bib-0004){ref-type="ref"}, [5](#rth212261-bib-0005){ref-type="ref"}. The PDC was calculated between the timeframe of the baseline‐initial DOAC treatment to last prescription of a DOAC without a further prescription of the same DOAC within 90 days for all atrial fibrillation patients included in our study. Since patients may stockpile their medications at home, overlaps between prescription dates were allowed and were included in the calculation of the PDC.

2.6. Outcome definitions {#rth212261-sec-0014}
------------------------

The outcome event, non‐persistence in those who were prescribed a DOAC, was defined as not registering a new prescription of any DOAC or VKA. Switchers were defined as the patients who discontinued initial DOAC treatment and switched to another oral anticoagulant drug. Hence, switchers formed a subgroup of the non‐persistent patients. In the VKA cohort, we considered VKA users non‐persistent when they completely stopped with VKA (i.e. were no longer receiving VKA therapy by the Leiden Anticoagulation Clinic).

2.7. Statistical analysis {#rth212261-sec-0015}
-------------------------

Baseline characteristics of the DOACs and VKA users are expressed as numbers and percentages, or as means and standard deviations (SD). The observation time was defined as the time between the first DOAC or VKA prescription date and the end of follow‐up. Follow‐up ended on the date of the last prescription (ie before the end of the study end‐date), or the study end date, whichever came first. Kaplan‐Meier analyses were used to determine cumulative incidences for an outcome event.

From the SFK database it cannot be established if a patient retrieves medication from different pharmacies at different times. If this occurs, it would seem that a patient was non‐persistent in pharmacy A, while the drugs were retrieved first in pharmacy A and then in pharmacy B. To account for such possible overestimation of non‐persistence, we excluded (in a sensitivity analysis) all patients who had the same birth year, sex, postal code, concomitant drug use, previous VKA use and who received the same initial DOAC during the observation period as another patient in the register, and repeated the aforementioned analysis to see if this would influence the main results.

In a Cox proportional hazard model we compared the likelihood of and the time to developing non‐persistence between the exposure groups, adjusting for age, sex, previous VKA use, high or low DOAC dose, socioeconomic status, concomitant drug use, and therapy adherence to DOAC, when applicable.

All statistical analyses were performed with SPSS for Windows, release 24.0 (SPSS).

3. RESULTS {#rth212261-sec-0016}
==========

3.1. Study population {#rth212261-sec-0017}
---------------------

We identified 92 718 patients who initiated treatment with DOAC between January 1, 2012 and April 1, 2016, based on the data provided by 1538 pharmacies in the Netherlands (79% of the total number of 1981 community pharmacies in the Netherlands in 2015; Figure [1](#rth212261-fig-0001){ref-type="fig"})[23](#rth212261-bib-0023){ref-type="ref"}. Figure [2](#rth212261-fig-0002){ref-type="fig"} describes the process of cohort selection. After we applied the inclusion criteria in which we separated prevalent DOAC users (n = 4826) from incident DOAC users (n = 87 352), and excluded patients in whom the DOAC type or dosage (n = 3427) was not reported or in whom two or more DOACs were prescribed at the same time (n = 12), there were 83 913 DOAC users of whom the majority (n = 77 333) were identified as atrial fibrillation patients. Baseline characteristics of these DOAC patients are shown in Table [1](#rth212261-tbl-0001){ref-type="table"}. The baseline characteristics of atrial fibrillation patients who used VKA (n = 10 079) are also shown in Table [1](#rth212261-tbl-0001){ref-type="table"}. DOAC patients were slightly younger than VKA users (70 vs 73 years), and slightly more than half of DOAC patients and VKA users were male (55% and 54%, respectively). Most patients on DOAC used rivaroxaban (n = 34 167; 44%), followed by dabigatran (n = 29 288; 38%) and apixaban (n = 13 878; 18%). The large majority (≥85%) of patients on DOAC had not used VKA before DOAC start. Patients with atrial fibrillation on low dose DOAC were older than patients with atrial fibrillation who received a high dose DOAC. This is as expected as prescription guidelines recommend a lower dose DOAC in patients who have chronic kidney disease (for all DOACs), or (for apixaban and dabigatran) are of older age[21](#rth212261-bib-0021){ref-type="ref"}. Therapy adherence was highest in apixaban users (n = 11 693, 84%), followed by dabigatran (n = 22 705, 78%) and rivaroxaban (n = 24 597, 72%). Other patient characteristics between the DOACs were roughly similar, with the exception of low dose DOAC patients on apixaban who were on average 3 and 6 years older than patients on rivaroxaban or dabigatran, respectively.

![Patients using a DOAC between 1 January 2012 and 1 April 2016\*. \*Data obtained from 1538 (79% of total) pharmacies in the Netherlands[22](#rth212261-bib-0022){ref-type="ref"}](RTH2-4-141-g001){#rth212261-fig-0001}

![Flow chart. AF, atrial fibrillation, DOAC, direct oral anticoagulants, VKA, vitamin K antagonist](RTH2-4-141-g002){#rth212261-fig-0002}

###### 

Baseline characteristics

                                                                DOAC use      Apixaban use   Rivaroxaban use   Dabigatran use   VKA use
  ------------------------------------------------------------- ------------- -------------- ----------------- ---------------- -----------
  Thromboembolic prevention in AF                                                                                               
  Any dose, n                                                   77 333        13 878         34 167            29 288           10 079
  Mean age, y (SD)                                              70 (11)       71 (11)        69 (11)           70 (11)          73 (11)
  Men, n (%)                                                    42 662 (55)   7814 (56)      18 133 (53)       16 715 (57)      5463 (54)
  Concomitant drug use, n (%)                                   66 351 (86)   12 280 (89)    28 864 (85)       25 207 (86)      NA
  Previous exposure to VKA, n (%)                               6356 (8)      2015 (15)      2610 (8)          1731 (6)         NA
  Socioeconomic class[a](#rth212261-note-0002){ref-type="fn"}                                                                   
  \>90% percentile, n (%)                                       7666 (10)     1156 (8)       3496 (10)         3014 (10)        NA
  Therapy adherent (PDC ≥80%)                                   58 995 (76)   11 693 (84)    24 597 (72)       22 705 (78)      NA
  Thromboembolic prevention in AF                                                                                               
  Low dose, n                                                   17 452        2171           4064              11 217            
  Mean age, y (SD)                                              76 (10)       80 (10)        77 (10)           74 (10)          NA
  Men, n (%)                                                    8357 (48)     919 (42)       1945 (48)         5493 (49)        NA
  Concomitant drug use, n (%)                                   15 171 (87)   1894 (91)      3592 (88)         9595 (86)        NA
  Previous exposure to VKA, n (%)                               1447 (8)      300 (14)       409 (10)          738 (7)          NA
  Socioeconomic class[a](#rth212261-note-0002){ref-type="fn"}                                                                   
  \>90% percentile, n (%)                                       1680 (10)     182 (8)        413 (10)          1085 (10)        NA
  Therapy adherent (PDC ≥80%)                                   13 245 (76)   1875 (86)      3188 (78)         8182 (73)        NA
  Thromboembolic prevention in AF                                                                                               
  High dose, n                                                  59 881        11 707         30 103            18 071            
  Mean age, y (SD)                                              68 (10)       69 (10)        68 (11)           67 (10)          NA
  Men, n (%)                                                    34 305 (57)   6895 (59)      16 188 (54)       11 222 (62)      NA
  Concomitant drug use, n (%)                                   51 180 (85)   10 296 (88)    25 272 (84)       15 612 (86)      NA
  Previous exposure to VKA, n (%)                               4909 (8)      1715 (15)      2201 (7)          993 (6)          NA
  Socioeconomic class[a](#rth212261-note-0002){ref-type="fn"}                                                                   
  \>90% percentile, n (%)                                       5986 (10)     974 (8)        3083 (10)         1929 (11)        NA
  Therapy adherent (PDC ≥80%)                                   45 750 (76)   9818 (84)      21 409 (70)       14 523 (80)      NA

Abbreviations: AF, atrial fibrillation; DOAC, direct oral anticoagulant; NA, not available; PDC, proportion of days covered; SD, standard deviation; VKA, vitamin K antagonist.

According to Statusscore of the Sociaal en Cultureel Plan Bureau, the Netherlands.

John Wiley & Sons, Ltd

3.2. Non‐persistence {#rth212261-sec-0018}
--------------------

The cumulative incidence of non‐persistence to anticoagulant treatment in patients starting with a DOAC is shown in Table [2](#rth212261-tbl-0002){ref-type="table"} and Figure [3](#rth212261-fig-0003){ref-type="fig"}. Non‐persistence was 8% at 6 weeks of follow‐up, 27% at 6 months, 34% at 1 year, 43% at 2 years, 51% at 3 years and 64% at 4 years of follow‐up. In Figure [2](#rth212261-fig-0002){ref-type="fig"}, Tables [S3](#rth212261-sup-0001){ref-type="supplementary-material"} and [S4](#rth212261-sup-0001){ref-type="supplementary-material"} the incidences of non‐persistence to anticoagulants are shown for apixaban, rivaroxaban, dabigatran and VKA. In the VKA cohort, the cumulative incidence of non‐persistence was 7% at 6 weeks of follow‐up, 16% at 6 months, 22% at 1 year, 28% at 2 years, 33% at 3 years and 36% at 4 years of follow‐up (Figure [3](#rth212261-fig-0003){ref-type="fig"} and Table [S4](#rth212261-sup-0001){ref-type="supplementary-material"}). For both DOAC and VKA use, the incidence of non‐persistence was highest in the first year of treatment.

###### 

Non‐persistent patients on DOAC and those who switched from their initial DOAC to another anticoagulant

  Follow‐up   Pt. at risk   Non‐persistent patients   Incidence of non‐persistence[a](#rth212261-note-0004){ref-type="fn"} (%)   Cumulative incidence[a](#rth212261-note-0004){ref-type="fn"} (%)   Pt. who switched initial DOAC   Percentage               
  ----------- ------------- ------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------- ------------ ---- ------ ----
  Any DOAC                                                                                                                                                                                                                                                   
  ≤6 wk       77 333        5781                      8                                                                          8                                                                  5912                            266          5    241    91
  6 wk‐6 mo   70 100        13 963                    19                                                                         27                                                                 14 661                          1139         8    726    64
  6‐mo‐1 y    44 569        3494                      7                                                                          34                                                                 4439                            1356         31   875    65
  1‐2 y       23 239        3150                      9                                                                          43                                                                 5058                            2543         50   1639   65
  2‐3 y       13 005        1372                      8                                                                          51                                                                 2622                            1657         63   1101   66
  3‐4 y       5301          593                       13                                                                         64                                                                 1931                            1572         81   1123   71
  Total                     28 353                    64                                                                                                                                            34 623                          8533         25   5705   67

Abbreviations: DOAC, direct oral anticoagulant; Pt, patients, VKA, vitamin K antagonist.

Estimated by cumulative incidence as determined from survival tables in Kaplan Meier analyses.

John Wiley & Sons, Ltd

![Cumulative incidence of non‐persistence to OAC treatment estimated by Kaplan‐Meijer analysis by type of OAC](RTH2-4-141-g003){#rth212261-fig-0003}

3.3. Patients who switched from their initial DOAC {#rth212261-sec-0019}
--------------------------------------------------

Of 77 333 patients who started with a DOAC, there were 8533 patients who switched to another anticoagulant of which the majority switched to VKA (n = 5705; 67%). Of these 8533 patients, 987 (13%) patients were non‐persistent to their oral anticoagulant treatment before the end of follow‐up and 383 (74%) discontinued their oral anticoagulant treatment after their switch after 1 year of follow‐up (Table [3](#rth212261-tbl-0003){ref-type="table"}). Similar non‐persistence and switching patterns were observed in a sensitivity analysis where we excluded potentially duplicate patients who might have retrieved their DOAC at different pharmacies (Table [S2](#rth212261-sup-0001){ref-type="supplementary-material"}).

###### 

Non‐persistence of patients who switched from their initial DOAC to another anticoagulant

  Follow‐up   Pt. at risk   Non‐persistent patients   Incidence of non‐persistence[a](#rth212261-note-0006){ref-type="fn"} (%)   Cumulative incidence[a](#rth212261-note-0006){ref-type="fn"} (%)   Non‐persistent patients after switch   Cumulative incidence[a](#rth212261-note-0006){ref-type="fn"} (%)        
  ----------- ------------- ------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------ -------------------------------------- ------------------------------------------------------------------ ---- ----
  Any DOAC                                                                                                                                                                                                                                                                                                         
  ≤6 wk       8533          135                       2                                                                          2                                                                  26                                     45                                                                 2    2
  6 wk‐6 mo   8265          441                       5                                                                          7                                                                  418                                    246                                                                10   12
  6 mo‐1 y    7127          411                       6                                                                          13                                                                 487                                    92                                                                 5    17
  1‐2 y       5771          635                       12                                                                         25                                                                 917                                    98                                                                 11   28
  2‐3 y       3228          407                       12                                                                         37                                                                 651                                    37                                                                 11   39
  3‐4 y       1571          234                       15                                                                         52                                                                 454                                    2                                                                  2    41
  Total                     2263                      52                                                                                                                                            2863                                   520                                                                41    

Abbreviation: DOAC, direct oral anticoagulant; Pts., patients.

Estimated by cumulative incidence as determined from survival tables in Kaplan Meier analyses.

John Wiley & Sons, Ltd

3.4. Variables related with non‐persistence in DOAC users {#rth212261-sec-0020}
---------------------------------------------------------

In multivariable analysis, non‐persistence to DOAC was related to age, where being younger increased the risk of discontinuing treatment (Table [4](#rth212261-tbl-0004){ref-type="table"}). No use of concomitant drugs and being non‐adherent (ie taking DOAC treatment according to prescription for \<80% of the time that DOAC treatment was used) also increased the likelihood of being non‐persistent to DOAC treatment. Furthermore, female sex increased the risk of being non‐persistent in apixaban, rivaroxaban and dabigatran users. Other variables, including being VKA experienced, whether or not receiving a high dose DOAC, and high neighbourhood socio‐economic class, produced hazard ratios that were not consistently associated with persistence for the DOACs tested. As we observed that the persistence rate reduced most steeply in the first year after DOAC initiation (Tables [2](#rth212261-tbl-0002){ref-type="table"} and [3](#rth212261-tbl-0003){ref-type="table"} and Tables [S3](#rth212261-sup-0001){ref-type="supplementary-material"} and [S4](#rth212261-sup-0001){ref-type="supplementary-material"}), we restricted follow‐up to the first year of DOAC use only in a post hoc analysis. This analysis also showed that of the clinical variables tested, younger age, female sex, no use of concomitant drugs and being non‐adherent were associated with higher risks of being non‐persistent. Figure [4](#rth212261-fig-0004){ref-type="fig"}A‐D shows the discontinuation and adherence rates in patients on DOAC who could be followed for at least 1 year. As the figure shows, most patients stopped their initial DOAC and did not restart their initial therapy.

###### 

Risk of being non‐persistent to DOAC according to clinical characteristics

                                                                    Observation months   Event no.   Hazard ratio (95% CI)[a](#rth212261-note-0008){ref-type="fn"}   Hazard ratio (95% CI)[a](#rth212261-note-0008){ref-type="fn"} ^,^ [b](#rth212261-note-0009){ref-type="fn"}
  ----------------------------------------------------------------- -------------------- ----------- --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Apixaban                                                                                                                                                           
  VKA naïve                                                         114 574              3028        1 (reference)                                                   1 (reference)
  VKA experienced                                                   12 107               252         0.95 (0.83‐1.09)                                                1.24 (1.10‐1.39)
  High dose DOAC                                                    106 854              2832        1 (reference)                                                   1 (reference)
  Low dose DOAC                                                     19 827               448         0.73 (0.66‐0.82)                                                0.83 (0.72‐0.89)
  Age \<60 y                                                        16 195               741         1 (reference)                                                   1 (reference)
  Age 60‐75 y                                                       66 871               1454        0.61 (0.55‐0.66)                                                0.66 (0.61‐0.73)
  Age \>75 y                                                        43 615               1085        0.75 (0.75‐0.83)                                                0.78 (0.70‐0.86)
  Men                                                               71 389               1909        1 (reference)                                                   1 (reference)
  Women                                                             55 292               1371        1.07 (0.99‐1.15)                                                1.12 (1.04‐1.20)
  No concomitant drug use                                           9080                 893         1 (reference)                                                   1 (reference)
  Concomitant drug use                                              117 601              2387        0.40 (0.36‐0.43)                                                0.39 (0.36‐0.42)
  SES class \<90th pctile[c](#rth212261-note-0010){ref-type="fn"}   115 939              2967        1 (reference)                                                   1 (reference)
  SES class \>90th pctile[c](#rth212261-note-0010){ref-type="fn"}   10 157               281         1.10 (0.97‐1.24)                                                1.05 (0.93‐0.19)
  Therapy adherent                                                  10 912               1603        1 (reference)                                                   1 (reference)
  Therapy non‐adherent                                              115 769              1677        8.58 (7.98‐9.23)                                                8.47 (7.88‐9.11)
  Rivaroxaban                                                                                                                                                        
  VKA naïve                                                         345 199              14 953      1 (reference)                                                   1 (reference)
  VKA experienced                                                   14 363               462         0.66 (0.60‐0.72)                                                0.88 (0.81‐0.95)
  High dose DOAC                                                    308 748              14 163      1 (reference)                                                   1 (reference)
  Low dose DOAC                                                     50 814               1252        0.63 (0.59‐0.66)                                                0.69 (0.65‐0.73)
  Age \<60 y                                                        56 038               2436        1 (reference)                                                   1 (reference)
  Age 60‐75 y                                                       197 443              7702        0.78 (0.75‐0.81)                                                0.79 (0.76‐0.83)
  Age \>75 y                                                        106 081              4277        0.86 (0.82‐0.90)                                                0.84 (0.80‐0.88)
  Men                                                               204 041              7182        1 (reference)                                                   1 (reference)
  Women                                                             155 521              8233        1.26 (1.22‐1.30)                                                1.32 (1.28‐1.37)
  No concomitant drug use                                           37 218               3684        1 (reference)                                                   1 (reference)
  Concomitant drug use                                              322 344              11 731      0.63 (0.61‐0.66)                                                0.63 (0.60‐0.65)
  SES class \<90th pctile[c](#rth212261-note-0010){ref-type="fn"}   317 656              13 913      1 (reference)                                                   1 (reference)
  SES class \>90th pctile[c](#rth212261-note-0010){ref-type="fn"}   39 824               1414        0.90 (0.85‐095)                                                 0.90 (0.84‐0.95)
  Therapy adherent                                                  53 405               8421        1 (reference)                                                   1 (reference)
  Therapy non‐adherent                                              306 157              6994        5.45 (5.28‐5.64)                                                5.19 (5.01‐5.37)
  Dabigatran                                                                                                                                                         
  VKA naïve                                                         457 449              9383        1 (reference)                                                   1 (reference)
  VKA experienced                                                   9077                 275         1.05 (0.93‐1.19)                                                1.65 (1.50‐1.82)
  High dose DOAC                                                    325 556              5674        1 (reference)                                                   1 (reference)
  Low dose DOAC                                                     140 970              3984        1.27 (1.22‐1.33)                                                1.42 (1.36‐1.49)
  Age \<60 y                                                        263 995              2163        1 (reference)                                                   1 (reference)
  Age 60‐75 y                                                       257 080              4606        0.67 (0.64‐0.71)                                                0.71 (0.67‐0.75)
  Age \>75 y                                                        145 451              2889        0.67 (0.63‐0.71)                                                0.66 (0.62‐0.71)
  Men                                                               272 887              5283        1 (reference)                                                   1 (reference)
  Women                                                             193 639              4375        1.11 (1.06‐1.15)                                                1.16 (1.11‐1.22)
  No concomitant drug use                                           39 594               2416        1 (reference)                                                   1 (reference)
  Concomitant drug use                                              426 932              7242        0.43 (0.41‐0.45)                                                0.43 (0.41‐0.45)
  SES class \<90th pctile[c](#rth212261-note-0010){ref-type="fn"}   418 315              8534        1 (reference)                                                   1 (reference)
  SES class \>90th pctile[c](#rth212261-note-0010){ref-type="fn"}   46 071               1051        1.04 (0.98‐1.11)                                                1.06 (0.99‐1.14)
  Therapy adherent                                                  59 573               4922        1 (reference)                                                   1 (reference)
  Therapy non‐adherent                                              406 953              4736        5.47 (5.25‐5.70)                                                5.85 (5.89‐6.12)

Abbreviations: DOAC, direct oral anticoagulant; pcetile, percentile; SES, socioeconomic class.

Multivariable adjusted.

Restricted to first year of DOAC use.

Defined by poste code area.

John Wiley & Sons, Ltd

![A‐D, Mean PDC of DOAC use for AF patients included before 01‐04‐2015 during follow‐up, and stratified for DOAC type n = 43 910](RTH2-4-141-g004){#rth212261-fig-0004}

4. DISCUSSION {#rth212261-sec-0021}
=============

In this population based study from the Netherlands, in patients who were identified as having atrial fibrillation, we observed that of DOAC users, 27% were non‐persistent to their anticoagulant treatment at 6 months, 34% at 1 year, 43% at 2 years and 64% at 4 years. These results are comparable to the non‐persistence rate at 2 years of follow‐up of 42% in a meta‐analysis of observational studies on cardiovascular drugs (like aspirin, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta‐blockers, calcium‐channel blockers, thiazides and statins) and to a non‐persistence rate of 42% of metformin at 2 years of follow‐up for patients with type 2 diabetes, in clinical settings without regular patient monitoring[24](#rth212261-bib-0024){ref-type="ref"}, [25](#rth212261-bib-0025){ref-type="ref"}.

Of the atrial fibrillation patients using VKA in our study, who were monitored in an anticoagulation clinic, 16% stopped at 6 months, 22% at 1 year, 28% at 2 years and 36% after 4 years of follow‐up. This is comparable to the non‐persistence rate for the DOACs in clinical trials where the non‐persistence rates was 21% for dabigatran at 2 years of follow‐up and 24% and 25% at a median of 2 years of follow‐up for rivaroxaban and apixaban, respectively[10](#rth212261-bib-0010){ref-type="ref"}, [11](#rth212261-bib-0011){ref-type="ref"}, [12](#rth212261-bib-0012){ref-type="ref"}.

4.1. Comparison with other studies {#rth212261-sec-0022}
----------------------------------

When we compare our results to other observational studies, one striking feature is the wide variety in reported non‐persistence of oral anticoagulant use amongst atrial fibrillation patients (Figure [5](#rth212261-fig-0005){ref-type="fig"})[8](#rth212261-bib-0008){ref-type="ref"}, [9](#rth212261-bib-0009){ref-type="ref"}, [26](#rth212261-bib-0026){ref-type="ref"}, [27](#rth212261-bib-0027){ref-type="ref"}, [28](#rth212261-bib-0028){ref-type="ref"}, [29](#rth212261-bib-0029){ref-type="ref"}, [30](#rth212261-bib-0030){ref-type="ref"}, [31](#rth212261-bib-0031){ref-type="ref"}, [32](#rth212261-bib-0032){ref-type="ref"}, [33](#rth212261-bib-0033){ref-type="ref"}, [34](#rth212261-bib-0034){ref-type="ref"}, [35](#rth212261-bib-0035){ref-type="ref"}, [36](#rth212261-bib-0036){ref-type="ref"}, [37](#rth212261-bib-0037){ref-type="ref"}, [38](#rth212261-bib-0038){ref-type="ref"}, [39](#rth212261-bib-0039){ref-type="ref"}, [40](#rth212261-bib-0040){ref-type="ref"}, [41](#rth212261-bib-0041){ref-type="ref"}, [42](#rth212261-bib-0042){ref-type="ref"}, [43](#rth212261-bib-0043){ref-type="ref"}. However, we could identify one common characteristic for the non‐persistence rates found in our and other observational studies for oral anticoagulants, which was whether or not patients were monitored on oral anticoagulant drugs. The non‐persistence rate in our VKA cohort (22% at 1 year at the Leiden Anticoagulation Clinic) was similar to those studies which only included patients on VKA who participated in the setting of an anticoagulation clinic (15% at 1 year) or where patients on VKA were regularly monitored by study design (18% at 1 year in one study, 22% in another and 26% at 1 year in another study)[28](#rth212261-bib-0028){ref-type="ref"}, [34](#rth212261-bib-0034){ref-type="ref"}, [37](#rth212261-bib-0037){ref-type="ref"}, [42](#rth212261-bib-0042){ref-type="ref"}. Moreover, the 28% non‐persistence rate at 2 years of follow‐up was comparable to those found for VKA in the RE‐LY trial (17% at 2 years of follow‐up), in the ARISTOTLE trial (28% at a median of 2 years of follow‐up) and in the ROCKET‐AF trial for (22% at a median of 2 years of follow‐up) in which patients were monitored closely[10](#rth212261-bib-0010){ref-type="ref"}, [11](#rth212261-bib-0011){ref-type="ref"}, [12](#rth212261-bib-0012){ref-type="ref"}. These results are also comparable to the non‐persistence rate of rivaroxaban in patients with atrial fibrillation from the Dresden registry (19% at an average of 1.5 years of follow‐up), in which patients were frequently monitored by study design[31](#rth212261-bib-0031){ref-type="ref"}. A similar non‐persistent rate of 23% at 2 years of follow‐up for dabigatran was found in an observational study by Paquette et al,[38](#rth212261-bib-0038){ref-type="ref"} where AF patients on dabigatran were regularly monitored by study design (at 3, 6, 12 and 24 months). In short, all studies that found a low non‐persistence rate for oral anticoagulant use amongst patients with atrial fibrillation had presence of patient monitoring in common[10](#rth212261-bib-0010){ref-type="ref"}, [11](#rth212261-bib-0011){ref-type="ref"}, [12](#rth212261-bib-0012){ref-type="ref"}, [28](#rth212261-bib-0028){ref-type="ref"}, [31](#rth212261-bib-0031){ref-type="ref"}, [34](#rth212261-bib-0034){ref-type="ref"}, [37](#rth212261-bib-0037){ref-type="ref"}, [38](#rth212261-bib-0038){ref-type="ref"}, [42](#rth212261-bib-0042){ref-type="ref"}.

![Percentage of non‐persistence at 12 months of OAC reported in our study and other observational studies. \#Studies in which % of non‐persistence at 12 months was read from KM‐analysis](RTH2-4-141-g005){#rth212261-fig-0005}

The high non‐persistence rates of DOAC use amongst patient with atrial fibrillation found in our study (34% for DOACs, 26% for apixaban, 27% for dabigatran and 42% for rivaroxaban, all at 1 year) were comparable to the non‐persistence found in other observational studies of patients using either VKA or DOACs after 1 year in which close patient monitoring was lacking[8](#rth212261-bib-0008){ref-type="ref"}, [9](#rth212261-bib-0009){ref-type="ref"}, [26](#rth212261-bib-0026){ref-type="ref"}, [27](#rth212261-bib-0027){ref-type="ref"}, [28](#rth212261-bib-0028){ref-type="ref"}, [29](#rth212261-bib-0029){ref-type="ref"}, [30](#rth212261-bib-0030){ref-type="ref"}, [32](#rth212261-bib-0032){ref-type="ref"}, [33](#rth212261-bib-0033){ref-type="ref"}, [34](#rth212261-bib-0034){ref-type="ref"}, [35](#rth212261-bib-0035){ref-type="ref"}, [36](#rth212261-bib-0036){ref-type="ref"}, [37](#rth212261-bib-0037){ref-type="ref"}, [39](#rth212261-bib-0039){ref-type="ref"}, [40](#rth212261-bib-0040){ref-type="ref"}, [41](#rth212261-bib-0041){ref-type="ref"}, [42](#rth212261-bib-0042){ref-type="ref"}, [43](#rth212261-bib-0043){ref-type="ref"}. Neither Germany or France have specialized anticoagulant clinics to monitor VKA users[44](#rth212261-bib-0044){ref-type="ref"}.

4.2. Explanations for low persistence {#rth212261-sec-0023}
-------------------------------------

Although we had no information on why patients were non‐persistent to their oral anticoagulant treatment, we found some persistence patterns that merit discussion: A *first potential reason* why patients were non‐persistent to their DOAC could be because the treatment was no longer indicated as patients\' heart rate returned to sinus rhythm[45](#rth212261-bib-0045){ref-type="ref"}. A large observational study showed that in patients with permanent atrial fibrillation at 1 year of follow‐up 8% were no longer in atrial fibrillation, and 6% were cured from atrial fibrillation[46](#rth212261-bib-0046){ref-type="ref"}. A similar finding was observed in the Dresden registry where 9% of patients with atrial fibrillation were non‐persistent with rivaroxaban (average follow‐up 1.5 years) as they had reverted to stable sinus rhythm[31](#rth212261-bib-0031){ref-type="ref"}. This does, however, not fully explain the high non‐persistence rate to DOAC use that we found. A *second potential reason* could be that patients who were non‐persistent died. However, mortality rates in atrial fibrillation patients on anticoagulants are approximately 1.5%‐1.7% per treatment year, and therefore mortality is also unlikely to fully explain the low persistence rates that we found[47](#rth212261-bib-0047){ref-type="ref"}. A *third potential reason* could be related with minor bleeding as it has been shown previously that approximately 30% of patients who are non‐persistent to their DOAC do this because of minor bleeding complications such as nose bleeds, haematuria or menorrhagia[31](#rth212261-bib-0031){ref-type="ref"}.

For example, women, who had a lower DOAC persistence in our study than men, receive relatively higher dosing of DOACs than men (pharmacokinetics; smaller volume of distribution, larger free fraction of drugs and slower clearance from the body)[48](#rth212261-bib-0048){ref-type="ref"}. Indeed, Frost et al,[49](#rth212261-bib-0049){ref-type="ref"} found that apixaban peak values were 18% higher in women than men. Another reason for poorer persistence among women could be due to longer and heavier menstruation cycles when using oral anticoagulants or vaginal blood loss in post‐menopausal women.[50](#rth212261-bib-0050){ref-type="ref"} As DOACs have relatively short half‐lives (rivaroxaban 5‐9 hours, dabigatran 12‐17 hours and apixaban 12 hours), DOAC concentrations peak shortly after intake, especially in those who use once daily doses of rivaroxaban,[49](#rth212261-bib-0049){ref-type="ref"}, [51](#rth212261-bib-0051){ref-type="ref"} which could further increase the risk of high DOAC levels leading to (minor) bleeding and non‐persistence. Therefore, high early peaks may be a *fourth potential reason* why patients are non‐persistent to their DOAC.

We also observed that 25%‐30% of patients, who were non‐persistent to their DOAC, switched from anticoagulant treatment and primarily switched to VKA, indicating that they did not tolerate their initial DOAC treatment (*fifth potential reason*). Again, we do not know why these patients switched from DOAC treatment, but results are in line with previous studies in which also approximately 6%‐16% of patients on DOAC who were non‐persistent to their initial treatment switched early in their therapy to another anticoagulant[2](#rth212261-bib-0002){ref-type="ref"}, [9](#rth212261-bib-0009){ref-type="ref"}, [26](#rth212261-bib-0026){ref-type="ref"}, [31](#rth212261-bib-0031){ref-type="ref"}.

A final *sixth potential reason* is that patients who were not adherent to DOAC therapy were also most likely to stop with DOAC treatment (hazard ratios of non‐persistence to DOAC were 6‐12 fold higher than for adherent DOAC users). This implies that poor adherence is a good predictor of DOAC non‐persistence, and some monitoring might therefore both increase treatment adherence and persistence.

Ultimately, the determinants of DOAC persistence in an individual patient likely exist as a complex of one or more factors that we summarized above and that can change over time.

4.3. Strengths and limitations {#rth212261-sec-0024}
------------------------------

A strength of our study is its population‐based design and hence its non‐selected participants. A limitation is that SFK does not provide information of the exact indication for DOAC treatment, although we could approximate this by the difference in first dose for atrial fibrillation as compared with venous thrombosis or thromboprophylaxis. Another potential limitation is that SFK was only able to provide data of 79% of all pharmacies in the Netherlands. The Reason for this is that not all pharmacies had provided complete data during the study period without switches in software systems. Therefore the reason for not including these pharmacies in our dataset was completely at random and it is therefore unlikely that this has effect the results.

We defined non‐persistence as follows: not registering a new prescription of any DOAC or VKA (ie those who intermittently used DOAC were included as being persistent to DOAC). Switchers were defined as the patients who discontinued initial DOAC treatment and switched to another oral anticoagulant drug. Hence, switchers formed a subgroup of the non‐persistent patients. There are however other ways to define non‐persistence eg by saying someone is non‐persistent when he or she did not take medication for a number of days in a row. We decided to not use the latter definition as some patients may have stopped DOAC treatment for an intermittent period for practical reasons, reasons that SFK data does not provide (eg failed to get new medication in time).

Another limitation is that we do not know the reasons why patients were non‐persistent to their oral anticoagulant treatment as this information was not available in our data sources. Although this was not our aim since we wanted to study the treatment persistence of DOACs and of VKA in patients with atrial fibrillation, reasons for being non‐persistent would be death or no longer in need of oral anticoagulant treatment, information that we could not retrieve from SFK. A further limitation is that in SFK, we used first dosage either with LMWH (for dabigatran) or double dosage (for apixaban and rivaroxaban) as an indicator if a patient used DOAC for atrial fibrillation or venous thrombosis as these prescriptions are provided by Dutch guidelines[21](#rth212261-bib-0021){ref-type="ref"}. However, we cannot be sure if physicians always strictly adhered to the guidelines. Therefore we may have misclassified patients with venous thrombosis as atrial fibrillation patients and vice versa. If patients with atrial fibrillation were prescribed an initial DOAC as required for venous thrombosis, these patients are missed in our analyses as they were considered as venous thrombosis patients (and therefore excluded). How often physicians prescribe a DOAC in the amount that would be required for atrial fibrillation (by definition a too low dose), we do not know, but consider it to occur only rarely. Indeed, another study from Denmark with a similar design as our study in which treatment indications could be distinguished found similar results as we reported here[26](#rth212261-bib-0026){ref-type="ref"}.

Furthermore, thromboprophylaxis with DOAC may have been given, at least in theory, in (higher) dosages that are usually only given in patients with atrial fibrillation. However, we consider this implausible, and since thromboprophylaxis with DOAC was only rarely prescribed to patients in the time period that we studied (as shown by the low frequency of DOAC use in thromboprophylactic dosage in our study), such a phenomenon, if it occurred, is unlikely to have materially affected our findings.

Finally, adherence was estimated for patients who continued or discontinued treatment for 90 days or less, and may have been erroneously estimated for those who stopped for a longer period and then restarted treatment or in those who temporarily stopped due to doctor\'s orders (eg elective surgery)[52](#rth212261-bib-0052){ref-type="ref"}. However the definition that we used for adherence is often used in pharmaco‐epidemiologic research[4](#rth212261-bib-0004){ref-type="ref"} and although it may be imprecise it is a clear indicator for non‐persistence, the outcome we were interested in for this analysis.

5. CONCLUSION {#rth212261-sec-0025}
=============

Persistence to DOAC treatment in our study was low and in line with results of observational studies into other preventive cardiovascular medication without patient monitoring. It was higher for VKA users with patient monitoring, which is also confirmative to other observational studies into medication where patient monitoring was performed. Our results show that worse persistence was clearly correlated with age \<60 years, with female sex and with non‐adherence to DOAC.
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